Overview

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin (EC-TCb) in triple-negative breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Epirubicin
Paclitaxel
Taxane